CRISPR Therapeutics rises on upbeat quarterly profit

Crispr Therapeutics AG

21/02/2024 15:34

(Updates)
    ** U.S.-listed shares  CRSP.O  of Swiss gene editing company
CRISPR Therapeutics up 2.6% at $80.8 
    ** Co posts Q4 profit of $1.10/shr vs loss of $1.41/shr a
year earlier
    ** Reports Q4 revenue of $201.2 mln vs est of $131.6 mln -
LSEG
    ** CRISPR and Vertex Pharmaceuticals'  VRTX.O  gene therapy
Casgevy is expected to launch in the United States early this
year for two different and approved inherited blood disorder
indications 
    ** Brokerage TD Cowen anticipates Casgevy sales much lower
than consensus to be recorded throughout 2024, saying key
opinion leaders expect commercial uptake to be a challenge due
to various limitations 
    ** As of last close, company's U.S.-listed shares up 54.7%
in past 12 months

 (Reporting by Puyaan Singh and Pratik Jain in Bengaluru)
 ((Puyaan.Singh@thomsonreuters.com))